Vor BioPharma appoints David Zaccardelli to board; director Andrew Levin resigns

Vor Biopharma Inc.

Andrew Levin resigned as director effective July 6, 2026; no disagreement with the company.
David Zaccardelli appointed as independent Class II director, term until 2029 annual meeting.
Zaccardelli is former CEO of Verona Pharma (acquired by Merck 2025), Dova, and Cempra.
He receives standard non-employee director compensation: $40k annual cash retainer, initial option grant of up to 68k shares or $700k.
No material transactions or arrangements exist between Zaccardelli and the company.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Andrew Levin

Director

VOR · Vor Biopharma Inc.

Effective: 2026-07-06
Successor: David Zaccardelli
Filed: July 7, 2026, 4:04 PM ET

On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation, effective immediately.

Appointed

David Zaccardelli

Director

VOR · Vor Biopharma Inc.

Effective: 2026-07-07
Filed: July 7, 2026, 4:04 PM ET

On July 7, 2026, the Board appointed David Zaccardelli, Pharm.D. to the vacancy created by Dr. Levin’s resignation, to serve on the Board as an independent Class II director until the Company’s 2029 annual meeting of stockholders and until his successor is duly elected and qualified or his earlier resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Levin resigned as Director at Vor Biopharma Inc..

Action: resigned
Role: Director

Exact text from the filing

On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Zaccardelli was appointed as Director at Vor Biopharma Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 7, 2026, the Board appointed David Zaccardelli, Pharm.D. to the vacancy created by Dr. Levin’s resignation, to serve on the Board as an independent Class II director until the Company’s 2029 annual meeting of stockholders and until his successor is duly elected and qualified or his earlier resignation or removal.

View on SEC.gov

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-297454

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.